Clonal gammopathies following alemtuzumab-based reduced intensity conditioning haematopoietic stem cell transplantation: Association with chronic graft-versus-host disease and improved overall survival

Bone Marrow Transplantation

Volumn 40, Issue 8, 2007, Pages 747-752

  Lim, Z Y ^a   Ingram, W ^a   Brand, R ^b   Akthari, M ^a   Milojkovic, D ^a   Ho, A Y L ^a   Devereux, S ^a   Pagliuca, A ^a   Duarte, R F ^a   Mufti, G J ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BUSULFAN; CYCLOSPORIN A; FLUDARABINE; IMMUNOGLOBULIN G;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC MYELOID LEUKEMIA; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DEATH; DISEASE ASSOCIATION; FEMALE; GLOBOID CELL LEUKODYSTROPHY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIVARIATE ANALYSIS; MYELODYSPLASTIC SYNDROME; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; PROTEIN ELECTROPHORESIS; REDUCED INTENSITY CONDITIONING; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; VIRUS INFECTION;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; MONOCLONAL GAMMOPATHIES, BENIGN; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING;

EID: 34948911148     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705805     Document Type: Article

References (21)

1. Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756-763.
2. Rouquette-Gally AM, Boyeldieu D, Prost AC, Gluckman E. Autoimmunity after allogeneic bone marrow transplantation. A study of 53 long-term-surviving patients. Transplantation 1988; 46: 238-240.
3. Sherer Y, Shoenfeld Y. Autoimmune diseases and autoimmunity post-bone marrow transplantation. Bone Marrow Transplant 1998; 22: 873-881.
4. Shenoy S, Mohanakumar T, Todd G, Westhoff W, Dunnigan K, Adkins D et al. Immune reconstitution following allogeneic peripheral blood stem cell transplants. Bone Marrow Transplant 1999; 23: 335-346.
5. Noel DR, Witherspoon RP., Storb R, Atkinson K, Doney K, Mickelson E et al. Does graft-versus-host disease influence the tempo of immunologic recovery after allogeneic human marrow transplantation? An observation on 56 long-term survivors. Blood 1978; 51: 1087-1105.
6. D'Sa S, Peggs K, Pizzey A, Verfuerth S, Thuraisundaram D, Watts M et al. T- and B-cell immune reconstitution and clinical outcome in patients with multiple myeloma receiving T-cell-depleted, reduced-intensity allogeneic stem cell transplantation with an alemtuzumab-containing conditioning regimen followed by escalated donor lymphocyte infusiods. Br J Haematol 2003; 123: 309-322.
7. Loh Y, Oyama Y, Statkute L, Quigley K, Yaung K, Gonda E et al. Development of a secondary autoimmune disorder after hematopoietic stem cell transplantation for autoimmune diseases: Role of conditioning regimen used? Blood 2007; 109: 2643-2648.
8. Ho AY, Pagliuca A, Kenyon M, Parker JE, Mijovic A, Devereux S et al. Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning. Blood 2004; 104: 1616-1623.
9. Mitus AJ, Stein R, Rappeport JM, Antin JH, Weinstein HJ, Alper CA et al. Monoclonal and oligoclonal gammopathy after bone marrow transplantation. Blood 1989; 74: 2764-2768.
10. Hammarstrom L, Smith CI. Frequent occurrence of monoclonal gammopathies with an imbalanced light-chain ratio following bone marrow transplantation. Transplantation 1987; 43: 447-449.
11. Nagashima T, Muroi K, Kawano-Yamamoto C, Komatsu N, Ozawa K. Paraproteinemia after hematopoietic stem cell transplantation. Leuk Lymphoma 2004; 45: 135-137.
12. Morecki S, Gelfand Y, Nagler A, Or R, Naparstek E, Varadi G et al. Immune reconstitution following allogeneic stem cell transplantation in recipients conditioned by low intensity vs myeloablative regimen. Bone Marrow Transplant 2001; 28: 243-249.
13. Buggins AG, Mufti GJ, Salisbury J, Codd J, Westwood N, Arno M et al. Peripheral blood but not tissue dendritic cells express CD52 and are depleted by treatment with alemtuzumab. Blood 2002; 100: 1715-1720.
14. Myint H, Copplestone JA, Orchard J, Craig V, Curtis D, Prentice AG et al. Fludarabine-related automimune haemolytic anaemia in patients with chronic lymphocytic leukaemia. Br J Haematol 1995; 91: 341-344.
15. Hebart H, Einsele H, Klein R, Fischer I, Buhler S, Dietz K et al. CMV infection after allogeneic bone marrow transplantation is associated with the occurrence of various autoantibodies and monoclonal gammopathies. Br J Haematol 1996; 95: 138-144.
16. Soderberg C, Larsson S, Rozell BL, Sumitran-Karuppan S, Ljungman P, Moller E. Cytomegalovirus-induced CD13-specific autoimmunity-a possible cause of chronic graft-vs-host disease. Transplantation 1996; 61: 600-609.
17. Moller E, Bohme J, Valugerdi MA, Ridderstad A, Olerup O. Speculations on mechanisms of HLA associations with autoimmune diseases and the specificity of 'autoreactive' T lymphocytes. Immunol Rev 1990; 118: 5-19.
18. Chakrabarti S, Mackinnon S, Chopra R, Kottaridis PD, Osman H, Waldmann H et al. High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: Potential role of Campath-1H in delaying immune reconstitution. Blood 2002; 99: 4357-4363.
19. Chakrabarti S, Avivi I, Mackinnon S, Ward K, Kottaridis PD, Osman H et al. Respiratory virus infections in transplant recipients after reduced-intensity conditioning with Campath-1H: High incidence but low mortality. Br J Haematol 2002; 119: 1125-1132.
20. Hanto DW, Frizzera G, Gajl-Peczalska KJ, Simmons RL. Epstein-Barr virus, immunodeficiency, and B cell lymphoproliferation. Transplantation 1985; 39: 461-472.
21. Miklos DB, Kim HT, Miller KH, Guo L, Zorn E, Lee SJ et al. Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. Blood 2005; 105: 2973-2978.